Guggenheim Rates Tenax Therapeutics (TENX) buy, $40 Price Target

Guggenheim maintains its buy rating on Tenax Therapeutics, setting a $40 target, a 209.36% upside from the current price.

By TradeTexts Research Desk · Published Jun 22, 2026, 10:01 AM EDT · Updated Jun 25, 2026, 11:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Tenax Therapeutics, Inc. ($TENX) "buy" with a $40 price target on June 22, 2026.

Since the rating, $TENX is up 10.2% after 1 week, up 20.7% after 1 month and down 88.9% to date (from the $12.25 close on Jun 22, 2026).

TENX Tenax Therapeutics, Inc.

$1.36 -87.69% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim reiterated its buy rating on Tenax Therapeutics, Inc. (TENX) with a target price of $40 as of June 22, 2026.
Guggenheim's $40 price target implies 209.36% upside from Tenax Therapeutics, Inc.'s ($TENX) current $12.93 share price.
Shares of NASDAQCM:TENX traded near $12.00 on Monday, with a 52-week range between $5.62 and $18.38.
Insiders including CFO Thomas Staab II have been buying shares, with significant positions also opened by institutional investors like Price T Rowe Associates.

Get $TENX trade alerts by text

We text you when insiders, Congress or big funds trade $TENX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tenax Therapeutics, Inc. alert may contain errors. Disclosures

Guggenheim reiterated its buy rating for Tenax Therapeutics, Inc. (NASDAQCM:TENX) on June 22, 2026, setting a price target of $40. Analyst Seamus Fernandez maintained the optimistic outlook for the biotechnology company, which focuses on novel cardiopulmonary therapies.

Other Institutional Activity in Tenax Therapeutics

Price T Rowe Associates Inc opened a new position in Tenax Therapeutics, acquiring 2,951,116 shares valued at about $47.19 million. Janus Henderson Group PLC increased its holdings by 1,648,808 shares to a total of 1,815,474 shares, worth approximately $29.07 million, marking a 989.3% increase. Venrock Adviser, LLC also initiated a stake with 1,675,262 shares valued at $26.79 million. Perceptive Advisors LLC expanded its position by 1,008,640 shares to 1,447,782 shares, valued at $23.15 million, a 229.7% increase. Ikarian Capital, LLC added 50,000 shares, bringing its total to 1,017,600 shares worth about $16.27 million, reflecting a 5.2% increase.

Tenax Therapeutics, Inc. Stock Up 580.5%

Shares of NASDAQCM:TENX traded near $12.00 on Monday. Tenax Therapeutics has a market cap of approximately $318.3 million. The stock's 52-week range is between $5.62 and $18.38, with a 50-day moving average of $12.47 and a 200-day moving average of $11.05. The company is not currently profitable, with a negative forward P/E ratio of -8.51. Tenax maintains a strong liquidity position with a current ratio of 14.52 and a quick ratio of 13.99.

12-month forecast

$TENX price target

Tenax Therapeutics, Inc. daily closes and this analyst's $40 target. Not advice.

Insider Buying and Selling at Tenax Therapeutics, Inc.

There has been notable insider buying activity at Tenax Therapeutics. On May 11, 2026, Chief Financial Officer Thomas Staab II purchased 450,000 shares. Earlier in the year, on January 30, 2026, Interim CFO Thomas McGauley bought 50,000 shares. Additionally, on January 9, 2026, insiders Declan Doogan and Michael Davidson each acquired 30,000 shares.

Analysts Set New Price Targets

On June 22, 2026, Guggenheim maintained its buy rating on Tenax Therapeutics with a $40 price target. On the same day, Chardan Capital initiated coverage with a buy rating and a $27 target. Earlier, Piper Sandler maintained a buy rating with a $50 target on June 12, 2026.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina. It focuses on developing novel therapies for cardiopulmonary diseases. The company is working on several treatments, including TNX-101, TNX-102, and TNX-103, which target pulmonary hypertension in heart failure patients. Tenax was founded in 1967 and is led by CEO Christopher T. Giordano.

Bottom Line

Guggenheim's reiterated buy rating and $40 target price reflect continued confidence in Tenax Therapeutics' potential. Investors follow analyst ratings closely, although these are based on past performance and expectations, not a guarantee of future results. As always, investors should consider multiple factors when evaluating a stock.